Related Experiment Videos
Angiogenesis for the treatment of vascular diseases
Insights
This study explored using vascular endothelial growth factor (VEGF) to promote new blood vessel growth in critical limb ischemia patients. Results showed new vessel growth, suggesting a potential new therapy for advanced vascular disease.
Area of Science:
- Vascular Biology
- Regenerative Medicine
Background:
- Critical limb ischemia often involves diffuse distal vascular disease, limiting conventional revascularization.
- Effective medical therapies for advanced limb ischemia are lacking.
- Therapeutic angiogenesis using vascular growth factors shows promise.
Discussion:
- A novel angiogenic strategy using vascular endothelial growth factor (VEGF) in a fibrin network was applied to two patients with critical limb ischemia.
- Fibrin glue facilitated sustained release of VEGF, promoting angiogenesis.
- Angiographic evidence demonstrated new blood vessel growth post-treatment.
Key Insights:
- VEGF-eluting fibrin composite successfully induced neovascularization in critical limb ischemia.
- This approach improved oxygenation in ischemic tissues.
- Demonstrated potential for treating advanced peripheral arterial disease.
Outlook:
- Further clinical investigations are needed to validate the efficacy of this angiogenic strategy.
- This method may offer a new treatment avenue for patients with diffuse distal vascular disease.
- Potential to increase blood flow and improve outcomes in advanced vascular disease.
Abstract:
Critical ischemia of the limbs or myocardium is frequently accompanied by diffuse distal vascular disease making it unapproachable by conventional revascularization techniques. Pharmacological treatment is available for coronary artery disease but there has been no effective medical therapy for advanced ischemia of the limbs. In the search for alternative treatments for patients with diffuse distal disease, recent developments in vascular biology have directed attention towards use of vascular growth factors. Therapeutic angiogenesis has shown promising results in early clinical studies as shown by improved clinical status and in some cases angiographic studies. We employed an angiogenic strategy that utilizes enhanced vascular endothelial growth factor (VEGF) in a fibrin network, in two patients with critical limb ischemia. Objectively, we were able to demonstrate angiographically the growth of new blood vessels after administration of VEGF and fibrin composite. Fibrin glue provides for the slow release of and prolongs the availability of VEGF, thereby sustaining angiogenesis resulting in improved oxygenation of ischemic tissue. Further investigations are warranted to validate if angiogenesis may increase blood flow in patients with advanced vascular disease.